|
PureTech Health PLC on Tuesday said it is launching a subsidiary focused on drugs to treat respiratory diseases. The Boston, Massachusetts-based biotech and pharmaceutical firm has named the new business Celea Therapeutics. Its lead drug candidate is deupirfenidone or LYT-100, which targets lung conditions. According to PureTech, LYT-100 ‘holds promise across multiple fibrotic and inflammatory lung conditions’, though its initial focus is idiopathic pulmonary fibrosis, a fatal form of tissue scarring. PureTech has promoted Sven Dethlefs, who has been involved in the drug’s development over the past year, to lead Celea. Dethlefs is the ex-chief executive of North America at Teva Pharmaceuticals Industries Ltd and a former partner at McKinsey & Co. ‘I believe deupirfenidone has the potential to be a true turning point in the treatment of IPF,’ Dethlefs said. ‘The strength of the clinical data, combined with the team and mission behind Celea, make this a uniquely compelling opportunity.’ PureTech completed a phase-2b trial of the drug back in December, and discussed the results with the US Food & Drug Administration. Celea plans to launch phase-3 testing by the end of the third quarter and is seeking external funding for the trial period, possibly through to commercialisation. PureTech shares were down 1.2% at 128.00 pence on Tuesday afternoon in London, and have fallen 24% in the last 12 months. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
